Glucagonoma maligno como causa infrecuente de diabetes de inicio

[1]  D. Coppola,et al.  NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor , 2010, Pancreas.

[2]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Ko,et al.  Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients , 2008, Annals of surgery.

[5]  B. Skogseid,et al.  Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years , 2007, Medical oncology.

[6]  M. Echenique-Elizondo,et al.  Síndrome del glucagonoma y seudoglucagonoma , 2004 .

[7]  A. V. van Beek,et al.  The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. , 2004, European journal of endocrinology.

[8]  J. Raoul,et al.  [Glucagonoma: a recent series of 7 cases]. , 2004, Bulletin du cancer.

[9]  W. Su,et al.  Necrolytic migratory erythema: clinicopathologic study of 13 cases , 2004, International journal of dermatology.

[10]  L. Kvols,et al.  The glucagonoma syndrome. Clinical and pathologic features in 21 patients. , 1996, Medicine.